GSK's Traber to lead FDA approval process for Pro-Pharmaceuticals drug

NEWTON, Mass. The acting chief medical officer for GlaxoSmithKline will lead a phase 3 trial for an investigational colorectal cancer treatment on behalf of Pro-Pharmaceuticals.

Peter Traber will lead the trial for Davanat, as well as the overall Food and Drug Administration approval process. Traber has served on Pro-Pharmaceuticals' board of directors since 2009, the drug maker said.

“Dr. Traber has a unique combination of medical, clinical drug development, management and regulatory experience,” said James Czirr, executive chairman for Pro-Pharmaceuticals. “We believe leveraging Dr. Traber’s extensive experience and success in designing and managing clinical trials will contribute significantly to our goal of commercializing Davanat.”